Aditxt (ADTX) Net Income towards Common Stockholders (2019 - 2026)
Aditxt (ADTX) recorded quarterly Net Income towards Common Stockholders of -$16.2 million in Q1 2026, down 209.47% quarter-over-quarter from -$5.2 million in Q4 2025, and down 171.97% on a YoY basis from $22.5 million in Q1 2025.
Aditxt (ADTX) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Aditxt's Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$16.2 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 171.97% year-over-year to -$16.2 million; the TTM figure through Mar 2026 stood at -$53.0 million (down 103.13% YoY), while the FY2025 annual figure was -$42.8 million, down 22.18% from the prior year.
- Net Income towards Common Stockholders was -$16.2 million for Q1 2026 at Aditxt, down from -$5.2 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.8 million in Q2 2022 to a low of -$24.2 million in Q3 2025.
- Historically, Net Income towards Common Stockholders has averaged -$8.8 million across 5 years, with a median of -$7.4 million in 2025.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders surged 70.96% in 2022, then slumped 246.8% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$8.2 million in 2022, then slumped by 35.28% to -$11.1 million in 2023, then jumped by 50.12% to -$5.5 million in 2024, then grew by 5.7% to -$5.2 million in 2025, then slumped by 209.47% to -$16.2 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$16.2 million (Q1 2026), -$5.2 million (Q4 2025), and -$24.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Aditxt | 2,485.68 | -2.16 Mn | 2,868.00 | -16.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.19 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | -24.21 Mn |
| Jun 30, 2025 | -7.40 Mn |
| Mar 31, 2025 | -5.95 Mn |
| Dec 31, 2024 | -5.55 Mn |
| Sep 30, 2024 | -6.98 Mn |
| Jun 30, 2024 | -7.62 Mn |
| Mar 31, 2024 | -14.87 Mn |
| Dec 31, 2023 | -11.12 Mn |
| Sep 30, 2023 | -9.91 Mn |
| Jun 30, 2023 | -5.68 Mn |
| Mar 31, 2023 | -5.98 Mn |
| Dec 31, 2022 | -8.22 Mn |
| Sep 30, 2022 | -7.56 Mn |
| Jun 30, 2022 | -1.79 Mn |
| Mar 31, 2022 | -6.06 Mn |
| Dec 31, 2021 | -24.05 Mn |
| Sep 30, 2021 | -9.76 Mn |
| Jun 30, 2021 | -6.18 Mn |